Lv4
698 积分 2025-04-29 加入
让期待的值得期待
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
1个月前
已完结
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
1个月前
已完结
Peripheral nervous system immune-related adverse events due to checkpoint inhibition
1个月前
已完结
Immune-Related Adverse Events of Immune Checkpoint Inhibitors
1个月前
已完结
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Nephrotoxicity: A Position Statement from the American Society of Onco-nephrology
1个月前
已完结
Soluble biomarkers for immune checkpoint inhibitor-related encephalitis: A mini-review
1个月前
已完结
The Current and Future of Biomarkers of Immune Related Adverse Events
1个月前
已完结
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases
1个月前
已完结
Use of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis
1个月前
已完结
Comparative effectiveness and safety of imported and domestic immune checkpoint inhibitors in China: a systematic review and pairwise and network meta-analyses
1个月前
已完结
皖公网安备34019202002308
